Since GPVI has a crucial role in arterial thrombosis in vivo3 and together with the fact that its deficiency is not associated with any major bleeding risk in humans or mice7, this receptor – for which there are no drugs in the market - is considered a hopeful target for the treatment of cardiovascular diseases providing a better risk/benefit ratio. This evidence concerns the gene GP6 and cardiovascular disorder.